Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics
1. Merck to acquire Cidara Therapeutics for $9.2 billion. 2. The deal aims to access a flu prevention drug.
FAQ
Why Bullish?
The acquisition by Merck suggests confidence in CDTX's pipeline, akin to historical biotech buyouts that have led to stock price increases.
How important is it?
The significant acquisition indicates potential growth for CDTX, making it highly relevant to its stock performance.
Why Long Term?
As development of flu prevention strategies evolves, CDTX's value may increase over time, reflecting long-term strategic gains.